Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Historical treatment-oriented fixed-combination table. Do not apply this renal interval to HIV PrEP or to tenofovir alafenamide combinations.
Check source scope before reading a dose
GlobalRPh RX List - TRUVADA
Product / population
Adult TRUVADA fixed-dose tablet; HIV treatment and HIV prevention have different renal restrictions.
Renal method
Estimated creatinine clearance (CrCl), mL/min. The selected subsection does not independently establish an estimating equation. The treatment table footnote specifies ideal (lean) body weight.
Source revision
Source revision date not established in selected retrieval.
Retrieved
2026-09-08
Local review status
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
TRUVADA: treatment interval reduction is not a PrEP strategy
The selected product source has different renal restrictions for treatment and prevention. Its treatment table also identifies ideal (lean) body weight.
What to reconcile: Confirm indication and source-defined clearance method before selecting an interval; do not transfer the treatment-only reduced-frequency regimen to PrEP.
GlobalRPh-hosted RX List · Adult TRUVADA fixed-dose tablet; HIV treatment and HIV prevention have different renal restrictions.
Renal method: Estimated creatinine clearance (CrCl), mL/min. The selected subsection does not independently establish an estimating equation. The treatment table footnote specifies ideal (lean) body weight. Source date: Source revision date not established in selected retrieval. Retrieved: 2026-09-08
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
For adult HIV treatment, the 200/300 mg tablet is given every 24 hours at CrCl >=50 mL/min and every 48 hours at 30 to 49. It is not recommended below 30, including hemodialysis. For PrEP, use is not recommended below CrCl 60; do not apply the treatment-only every-48-hour schedule to prevention. Clinical efficacy of the renal interval adjustment has not been evaluated, and pediatric renal dosing data are insufficient.
RDM45-rxlist-truvada-5669425f1b-C1 · Source locator: Dosage Adjustment for Renal Impairment and Table 1, lines 85-101.
Estimated creatinine clearance (CrCl), mL/min. The selected subsection does not independently establish an estimating equation. The treatment table footnote specifies ideal (lean) body weight.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.